非小细胞肺癌患者血清miR-133b的表达水平及其临床意义探讨

Serum miR-133b levels and its relation with clinical pathological characteristics in non-small cell lung cancer patients

目的:探讨非小细胞肺癌患者血清miR-133b的表达水平与临床病理特征及疾病预后的关系。方法:将80例经病理活检证实为非小细胞肺癌患者纳入此次研究的对象,同期选取进行体检的健康人群80例作为正常对照组,采用real-time荧光定量PCR方法检测所有人员血清miR-133b的表达水平,进一步分析非小细胞肺癌患者血清miR-133b的表达水平与患者的临床及病理特征的关系。结果:非小细胞肺癌患者血清miR-133b表达水平(0.86±1.27)显著低于正常对照组的表达水平(1.78±1.36),差异具有统计学意义(t=9.572,P=0.004)。非小细胞肺癌患者血清miR-133b的表达水平与病理分期、肿瘤分化程度、抽烟史及是否发生淋巴结转移等因素密切相关(P<0.05),与患者年龄、性别、肿瘤直径及病理分型无关(P>0.05);非小细胞肺癌患者术后miR-133b高表达者1年内的生存率(73.8%)明显高于miR-133b低表达者(52.6%),差异具有统计学意义(χ2=8.580,P=0.003)。结论:血清miR-133b的检测有助于早期对非小细胞肺癌进行筛选与诊断,其表达与非小细胞肺癌临床及病理特征、治疗后存活时间具有明显的相关性,对评估非小细胞肺癌的预后具有一定价值。

Objective： To explore the relationship between serum miR-133 b levels and clinical pathological characteristics,as well as prognosis of disease in non-small cell lung cancer patients. Methods： A total of 80 patients were diagnosed as non- small cell lung cancers by pathological biopsy were included in this study.Meanwhile,80 health people underwent health examinations were selected as controls. The levels of serum miR-133 b were measured by real-time PCR. Results： The serum miR-133 b level in non-small cell lung cancer patients was（ 0. 86 ± 1. 27）,which was obviously lower than that of the normal controls（ 1. 78 ± 1. 36）（ t = 9. 572,P =0. 004）,and the differences had significance（ P〈0. 05）. The serum miR-133 b levels were related to the pathologic stage,tumor differentiation grade,smoking history and lymph node metastasis（ P〈0. 05）. The patients with high expression of serum miR-133 b levels had greater 1-year survival rates than those of the low expression of serum miR-133 b patients（ 52. 6%）（ χ^2= 8. 580,P = 0. 003）. Conclusion： Detection of serum miR-133 b levels is beneficial for early screening and diagnosing non- small cell lung cancers. Closely related to the clinical pathological characteristics,survival times after treatment,it is a valuable tool for evaluating the prognosis of nonsmall cell lung cancer patients.